Callan Family Office’s Vertex Pharmaceuticals VRTX Stock Holding History

Callan Family Office’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.82M	Buy	15,262 +822	+6%	+$383K	0.15%	143
2025 Q4	$6.55M	Buy	14,440 +3,235	+29%	+$1.39M	0.14%	149
2025 Q3	$4.39M	Sell	11,205 -5,510	-33%	-$2.3M	0.14%	156
2025 Q2	$7.44M	Buy	16,715 +11,198	+203%	+$5.16M	0.23%	95
2025 Q1	$2.67M	Buy	5,517 +3,067	+125%	+$1.43M	0.2%	109
2024 Q4	$987K	Buy	+2,450	New	+$1.14M	0.06%	257

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Callan Family Office's VRTX Position: Q1 2026 in Review

Callan Family Office increased its Vertex Pharmaceuticals (VRTX) stake by 5.7% in Q1 2026, buying an estimated $383K and bringing the position to 15,262 shares worth $6.82M. The position accounts for 0.15% of the portfolio, ranked #143.

Callan Family Office first reported a position in VRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $7.44M in Q2 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Callan Family Office held 15,262 shares of Vertex Pharmaceuticals worth $6.82M as of Q1 2026.
Callan Family Office bought 822 Vertex Pharmaceuticals shares in Q1 2026, an estimated $383K.
Vertex Pharmaceuticals made up 0.15% of Callan Family Office's portfolio in Q1 2026, its #143 holding.
Callan Family Office first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
Callan Family Office's Vertex Pharmaceuticals position peaked at $7.44M in Q2 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.